Ampio plummets on Phase III osteoarthritis miss

Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) fell $5.18 (66%) to $2.69 on Monday after osteoarthritis pain relief candidate Ampion missed the primary endpoint in the Phase III STRIDE trial. Ampio said it will meet with FDA to discuss the submission of a BLA for Ampion based on data from previous clinical trials.

Ampion did reduce WOMAC-A pain subscale scores significantly from baseline in the trial, but Ampio said response to a saline control in STRIDE's placebo arm was twice as variable as observed in previous trials. The company said it will re-examine patient demographic differences between STRIDE and earlier trials. ...